/

RYTM

Rhythm Pharmaceuticals, Inc.Pre-market

89.82−0.96 −1.06%USD

NasdaqGM · as of Oct 12, 16:00 ET · 15m delayPre-market 89.82 0.00%

Open

91.05

Prev close

90.78

Day range

89.4991.42

52-week range

74.50122.20

Volume

540.78K0.81×

Mkt cap

6.18B

P/E ttm

—

Fwd P/E

-143.88

EPS ttm

-3.12

Div yield

0.00%

Earnings

Aug 4, 2026

From 52w high

−26.50%

Price Chart

Yahoo Finance · delayed

RYTMOct 12, 2026O 91.05H 91.42L 89.49C 89.82−0.96 (−1.06%)Vol 543.80K

SMA 50103.69
SMA 20098.23

1Y change −10.91% since Oct 10, 2025 close539 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

RYTM Rhythm Pharmaceuticals, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −2.84%
1 month: −14.22%
3 months: −16.44%
6 months: +3.47%
Year to date: −16.09%
1 year: −10.91%

Valuation & ownership

Market cap: 6.18B
Enterprise value: 6.08B
P/E (ttm): —
Forward P/E: -143.88
PEG ratio: —
Price / book: 60.04
Price / sales (ttm): 25.78
EV / EBITDA: -30.46
EPS (ttm): -3.12
EPS (forward): -0.6243
Beta (5y monthly): 2.01
Dividend yield: 0.00%
Payout ratio: —
Shares outstanding: 68.85M
Float: 56.04M
Short % of float: 15.76%
Short ratio (days): 16.33
Held by insiders: 0.70%
Held by institutions: 114.85%
Avg volume (3m): 671.73K
50-day average: 103.69
200-day average: 98.23
52-week change: −10.91%
S&P 500 52-week: +17.50%

Technicals (daily)

RSI (14): 30.4
vs 50-day SMA: −13.38%
vs 200-day SMA: −8.56%
50 / 200-day trend: ▲ 50 above 200
MACD vs signal: ▼ below
ATR (14) % of price: 4.12%
Realised vol (20d, ann.): 27.9%
From 52-week high: −26.50%
From 52-week low: +20.56%

ANR

Analyst Consensus

17 analysts

Consensus

Strong buy

1.50 on a 1 (strong buy) – 5 (sell) scale

Mean target

140.35

+56.26% implied

Low 120.00Median 143.00High 160.00

Recommendation trend

Now16 / 2 / 0
1m ago / 2 /

DES

About Rhythm Pharmaceuticals, Inc.

Yahoo Finance profile

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, Bardet-Biedl and Alström syndrome, Prader-Willi syndrome, and hypothalamic obesity. It is in Phase 3 clinical trials for treating acquired hypothalamic obesity, congenital hypothalamic obesity, pro-opiomelanocortin (POMC) and LEPR insufficiency obesities, SRC1 deficiency obesity, and SH2B1 deficiency obesity; and in phase 2 clinical trails for the treatment of Prader-Willi syndrome and MC4R deficiency. The company is also developing bivamelagon, an investigational oral small molecule MC4R agonist that is in phase 2 clinical trial for the treatment of MC4R pathway diseases; and RM-718, a next generation MC4R peptide agonist that is in phase 1 clinical trial for the treatment of hypothalamic obesity. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Sector: Healthcare
Industry: Biotechnology
Employees: 414
Headquarters: Boston, MA, United States
Website: rhythmtx.com
Officers: Dr. David P. Meeker M.D. Chairman, President & CEO

SEAS

Seasonality · RYTM

2017–2026 · monthly returns

Strongest month Jul +28.17%Weakest month May −6.20%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-4.2	-9.5	-6.2	-6.5	8.6	25.7	-10.6	6.9	-10.3	-5.7			−16.1%
2025	6.2	-7.6	-3.5	23.1	-5.9	3.0	34.9	21.0	-2.1	12.6	-4.1	-1.9	+91.2%
2024	-4.0	-1.6	-0.2	-8.2	-10.3	15.1	17.4	-1.9	10.8	-8.9	30.0	-9.8	+21.8%
2023	-6.1	-11.1	-26.6	13.1	-17.4	-1.0	8.2	45.8	-11.9	0.8	44.7	37.5	+57.9%
2022	-25.8	2.8	51.2	-45.7	-45.0	20.6	203.6	79.4	8.4	2.7	6.4	8.8	+191.8%
2021	3.2	-15.5	-17.9	1.4	-9.0	-0.2	-11.7	-24.8	0.4	-11.9	-22.2	11.5	−66.4%
2020	-23.6	8.8	-20.2	23.8	2.9	15.0	-13.8	53.5	-26.6	-2.3	46.2	-3.9	+29.5%
2019	-1.0	7.8	-4.4	-7.8	-0.4	-12.7	-12.5	17.0	-4.1	-1.3	5.3	2.3	−14.6%
2018	8.6	-18.1	-23.0	19.1	35.5	-2.7	-0.7	1.5	-7.4	-4.0	5.4	-9.0	−7.5%
2017											11.7	1.7	+13.6%

INSD

Insider Activity · RYTM

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

284.9K shares

Sells, 6 months

300.1K shares

Net shares

−15.2K

Net change in insider shares

−3.10%

Date	Insider	Transaction	Shares	Value
Sep 13, 2026	Meeker David PChief Executive Officer	Sale at price 101.75 - 105.19 per share.	50K	$5.13M
Sep 13, 2026	Meeker David PChief Executive Officer	Conversion of Exercise of derivative security at price 6.05 per share.	50K	$302.50K
Aug 30, 2026	Smith Hunter CChief Financial Officer	Sale at price 104.59 - 106.20 per share.	62.8K	$6.62M
Aug 30, 2026	Smith Hunter CChief Financial Officer	Conversion of Exercise of derivative security at price 25.79 per share.	57.2K	$1.47M
Aug 12, 2026	Lee Jennifer KaydenOfficer	Sale at price 117.38 per share.	75.8K	$8.90M
Aug 12, 2026	Lee Jennifer KaydenOfficer	Conversion of Exercise of derivative security at price 6.80 - 24.29 per share.	56.6K	$997.04K
Aug 12, 2026	Shulman Joseph JChief Technology Officer	Sale at price 119.75 per share.	5.1K	$608.21K
Aug 12, 2026	Shulman Joseph JChief Technology Officer	Conversion of Exercise of derivative security at price 6.80 per share.	2K	$13.76K
Aug 12, 2026	Garfield Alastair Ph.D.Officer	Sale at price 116.11 - 119.17 per share.	7.8K	$912.70K
Aug 11, 2026	Mazabraud YannOfficer	Sale at price 111.80 - 117.47 per share.	57K	$6.62M
Aug 11, 2026	Mazabraud YannOfficer	Conversion of Exercise of derivative security at price 6.80 per share.	46.6K	$317.05K
Jun 30, 2026	Garfield Alastair Ph.D.Officer	—	4.4K	—
Jun 22, 2026	Good Jennifer LDirector	—	4.7K	—
Jun 22, 2026	Mcgirr David W JDirector	—	4.7K	—
Jun 22, 2026	Jean Christophe RDirector	—	4.7K	—
Jun 22, 2026	Arbuckle Stuart ADirector	—	4.7K	—
Jun 22, 2026	Tetrault Lynn A.Director	—	4.7K	—
Jun 21, 2026	Tetrault Lynn A.Director	Sale at price 100.32 per share.	37K	$3.71M
Jun 21, 2026	Tetrault Lynn A.Director	Conversion of Exercise of derivative security at price 28.27 per share.	37K	$1.05M
May 17, 2026	Smith Hunter CChief Financial Officer	Conversion of Exercise of derivative security at price 17.87 per share.	3K	$53.61K

13F

Investors Holding RYTM

latest 13F filings of 29 followed managers

Investors holding RYTM
Investor	Value	Of portfolio	Shares	Change	Quarter
Duquesne Family Office · Stanley Druckenmiller	$22.6M	0.43%	203.62K	New	Q2 2026
Renaissance Technologies	$7.6M	0.01%	68.28K	−74%	Q2 2026

From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors

RYTM

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

RYTM

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Rhythm Pharmaceuticals, Inc.

Seasonality · RYTM

Insider Activity · RYTM

Congress Trades · RYTM

Investors Holding RYTM

Investors Holding RYTM

Congress Trades · RYTM

Insider Activity · RYTM

Seasonality · RYTM

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Rhythm Pharmaceuticals, Inc.

Financial Snapshot

Earnings & Dividends

News